Video

Appropriate use criteria for PSMA-PET imaging will help guide clinicians

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, discusses what he hopes clinicians and patients take away from the recently released appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging in prostate cancer. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.

      Related Videos
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Sarah Razavi, MD, answers a question during a Zoom video interview
      Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Considerations for patient follow-up after onabotA administration
      Considerations for patient follow-up after onabotA administration
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Administering onabotA: Improving patient comfort and easing anxiety
      Administering onabotA: Improving patient comfort and easing anxiety
      Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
      Expert discusses genitourinary syndrome of menopause guidelines
      Related Content
      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
      April 8th 2025

      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

      Phillip Kuo, MD, PhD Hannah Clarke
      "For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
      June 22nd 2023

      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

      Urology Times staff
      "We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
      March 31st 2025

      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

      Phillip Kuo, MD, PhD
      "I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
      Study finds geographic disparities in MRI use in prostate cancer
      March 27th 2025

      Study finds geographic disparities in MRI use in prostate cancer

      Hannah Clarke
      The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.
      FDA approves PET imaging product Gozellix for prostate cancer
      March 20th 2025

      FDA approves PET imaging product Gozellix for prostate cancer

      Hannah Clarke
      Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
      March 6th 2025

      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

      Hannah Clarke
      The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
      © 2025 MJH Life Sciences

      All rights reserved.